Squires Again Broadens Discretion for Post-Grant Proceedings
March 13, 2026, 8:14 AM
By: Aziz Burgy, Brian P. Johnson, Joseph A. Micallef, Jerome P. David, Jerome P. David
On Wednesday, March 11, 2026, United States Patent and Trademark Office (USPTO) Director John Squires issued a memorandum[1] announcing that when making institution decisions in inter partes review (IPR) and post-grant review (PGR) proceedings, he would consider whether accused or licensed products and components were manufactured in the United States, as well as whether the petitioner was a small business that had been sued for infringement. The Director’s stated concern is perceived threats to America’s innovation leadership caused by substantial movement of the country’s manufacturing base overseas. Squires noted that much of this movement happened when IPR and PGR proceedings had a broad institution framework, and that many of the most frequent filers of such proceedings are large companies that conducted most of their manufacturing offshore.
The Director’s reasoning in this memorandum appears to be in line with his previous policies on institution decisions and concerns about foreign threats. In October 2025, he issued a memorandum requiring disclosure of real parties in interest in IPR petitions, based partially on concerns that the IPR process had been exploited by foreign state-backed actors.
This latest memorandum is an extensive and novel expansion of what the Director will consider under his discretion in an institution decision. While IPR and PGR proceedings assess the patentability of a patent claim, this new focus on the manufacturing location of products and related components incorporates elements related to commercialization into the institution decision. Ultimately, the memorandum offers new institution arguments for small and/or domestic petitioners, while implicitly limiting the IPR and PGR prospects of foreign manufacturers.
[1] The memorandum applies to all IPRs and PGRs where the due date for a patent owner discretionary brief has not yet elapsed.

To subscribe to our publications, click here.
News & Insights
News & Insights
CCWC 22nd Annual Career Strategies Conference
Sponsorship
Fordham Competition Law Institute's 53rd Annual Conference on International Antitrust Law and Policy, and Antitrust Economics Workshop
Sponsorship
Antitrust
Women, Influence, & Power in Law Conference 2026
Sponsorship
Antitrust
IP Litigation North America Summit 2026
Sponsorship
Intellectual Property
HNBA/VIA Annual Convention 2026
Sponsorship
Antitrust
30th Annual IBA Competition Conference
Speaking Engagement
Antitrust
ABA 2026 Antitrust Global Seminar Series
Speaking Engagement
Antitrust
Axinn Attorneys Earn Top Honors in Best Lawyers 2027
News
Antitrust
DOJ's Antitrust Division Remains Interested in Your Private Litigation
Byline Articles
Antitrust
Axinn Advises Thermo Fisher Scientific on Completed $1.075 Billion Sale of Microbiology Business to Astorg
Deals & Cases
Antitrust